Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ibrexafungerp→

Ibrexafungerp Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1207753-03-4
Molecular formula
C44H67N5O4
Molecular weight
730.05 g/mol
Drug class
Oral triterpenoid antifungalfungal 1,3-beta-D-glucan synthase inhibitor
Mechanism of action
Inhibits fungal 1,3-beta-D-glucan synthase, disrupting synthesis of an essential component of the fungal cell wall and causing structural instability and cell death.
Indications / reported uses
  • Treatment of vulvovaginal candidiasis (VVC) in adult and postmenarchal paediatric patients
  • Reduction in the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal paediatric patients after treatment of the current episode; regimen and indication are product-label specific

Sources: US DailyMed — BREXAFEMME (ibrexafungerp) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ibrexafungerp Environmental Risk Assessment (ERA) (the Ibrexafungerp ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.